Borda Miguel German, Ramírez-Vélez Robinson, Botero-Rodriguez Felipe, Patricio-Baldera Jonathan, de Lucia Chiara, Pola Ilaria, Barreto George E, Khalifa Khadija, Bergland Anne Katrine, Kivipelto Miia, Cederholm Tommy, Zetterberg Henrik, Ashton Nicholas J, Ballard Clive, Siow Richard, Aarsland Dag
Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Helse Stavanger HF, Postboks 8100, 4068, Stavanger, Norway.
Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
Geroscience. 2025 May 2. doi: 10.1007/s11357-025-01669-8.
Anthocyanins are dietary flavonoids shown to have a therapeutic capacity to mitigate inflammation and oxidative stress. The present secondary analyses from the "Anthocyanins in People at Risk for Dementia Study" were aimed at (I) determining the intervention's effect on blood-based markers of cardiovascular disease and inflammation and (II) evaluating whether baseline factors such as age, sex, inflammation, or cardiometabolic score may moderate the intervention's effect on inflammatory status. This study was an ancillary, 24-week randomized, double-blind, placebo-controlled Phase II trial. Sub-sample participants (n = 99), aged 60-80 years with mild cognitive impairment or cardiometabolic disorders, were randomized to receive either 320 mg/day of anthocyanins or placebo. The biomarkers analyzed included inflammatory biomarker assessment (IL - 6, IL - 8, IL - 10, IL - 1b, TNF - α, IFN - γ), and C-reactive protein (CRP), as well as albumin, thrombocytes, cholesterol, LDL, HDL, and triglycerides, which were longitudinally compared between both groups. Baseline characteristics were balanced between the groups. ANCOVA analyses reveal 24-week differences favoring the anthocyanin treatment in LDL cholesterol levels (ƞp = 0.078; p = 0.015), cardiometabolic score (ƞp = 0.073; p = 0.021), CRP levels (ƞp = 0.417; p = 0.0001), IL - 6 (ƞp2 = 0.085; p = 0.015), IL - 1b (ƞp = 0.058; p = 0.037), and Inflam z-score 5 (ƞp = 0.059, p = 0.004). Moderation analysis demonstrated that the inflammatory score at baseline was a significant predictor of the effect of the intervention on the CRP levels. Anthocyanin supplementation reduces CRP and cardiovascular disease biomarkers in individuals at risk of dementia, especially when there is increased inflammation at baseline. ClinicalTrials.gov study identifier: NCT03419039.
花青素是一类膳食类黄酮，已证明具有减轻炎症和氧化应激的治疗能力。“痴呆症风险人群中的花青素研究”的本次二次分析旨在：（I）确定干预措施对心血管疾病和炎症的血液标志物的影响；（II）评估年龄、性别、炎症或心脏代谢评分等基线因素是否会调节干预措施对炎症状态的影响。本研究是一项辅助性的、为期24周的随机、双盲、安慰剂对照的II期试验。对年龄在60 - 80岁、患有轻度认知障碍或心脏代谢紊乱的子样本参与者（n = 99）进行随机分组，分别接受每日320毫克花青素或安慰剂。分析的生物标志物包括炎症生物标志物评估（IL - 6、IL - 8、IL - 10、IL - 1b、TNF - α、IFN - γ）和C反应蛋白（CRP），以及白蛋白、血小板、胆固醇、低密度脂蛋白、高密度脂蛋白和甘油三酯，并对两组进行纵向比较。两组之间的基线特征是平衡的。协方差分析显示，在24周时，花青素治疗在低密度脂蛋白胆固醇水平（ƞp = 0.078；p = 0.015）、心脏代谢评分（ƞp = 0.073；p = 0.021）、CRP水平（ƞp = 0.417；p = 0.0001）、IL - 6（ƞp2 = 0.085；p = 0.015）、IL - 1b（ƞp = 0.058；p = 0.037）和炎症z评分5（ƞp = 0.059，p = 0.004）方面存在有利于花青素治疗的差异。调节分析表明，基线时的炎症评分是干预措施对CRP水平影响的显著预测指标。补充花青素可降低痴呆症风险个体的CRP和心血管疾病生物标志物水平，尤其是在基线炎症增加的情况下。ClinicalTrials.gov研究标识符：NCT03419039。
